Patients with dermatomyositis shared partially similar transcriptome signature with COVID-19 infection

References

• Bottai M, Tjarnlund A, Santoni G, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. Rmd Open. 2017;3(2):1.
   Google Scholar
• Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015;54(1):50–9.
   PubMed Web of Science ®Google Scholar
• Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45(5):676–683.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):293–302.
   PubMed Web of Science ®Google Scholar
• Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011;13(3):225–232.
   PubMed Web of Science ®Google Scholar
• Gao S, Luo H, Zhang H, et al. Using multi-omics methods to understand dermatomyositis/polymyositis. Autoimmun Rev. 2017;16(10):1044–1048.
   PubMed Web of Science ®Google Scholar
• Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014;53(3):397–405.
   PubMed Web of Science ®Google Scholar
• Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010;1184:134–153.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz R, Niewold TB. Type I interferons in autoimmunity. J Invest Dermatol. 2022;142(3 Pt B):793–803.
   PubMed Web of Science ®Google Scholar
• Bolko L, Jiang W, Tawara N, et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021;31(3):e12955.
   PubMed Web of Science ®Google Scholar
• Arshanapalli A, Shah M, Veerula V, et al. The role of type I interferons and other cytokines in dermatomyositis. Cytokine. 2015;73(2):319–325.
   PubMed Web of Science ®Google Scholar
• Behan WM, Behan PO. The role of viral infection in polymyositis, dermatomyositis and chronic fatigue syndrome. Baillieres Clin Neurol. 1993;2(3):637–657.
   PubMedGoogle Scholar
• Peravali R, Acharya S, Raza SH, et al. Dermatomyositis developed after exposure to Epstein-Barr virus infection and antibiotics use. Am J Med Sci. 2020;360(4):402–405.
   PubMed Web of Science ®Google Scholar
• Qian J, Xu H. COVID-19 disease and dermatomyositis: a mini-review. Front Immunol. 2021;12:747116.
   PubMed Web of Science ®Google Scholar
• Gupta L, Lilleker JB, Agarwal V, et al. COVID-19 and myositis – unique challenges for patients. Rheumatology (Oxford). 2021;60(2):907–910.
   PubMed Web of Science ®Google Scholar
• Tanboon J, Nishino I. COVID-19-associated myositis may be dermatomyositis. Muscle Nerve. 2021;63(1):E9–E10.
   PubMed Web of Science ®Google Scholar
• Domizio JD, Gulen MF, Saidoune F, et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature. 2022;603(7899):145–151.
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–29.
   PubMed Web of Science ®Google Scholar
• Ogata H, Goto S, Sato K, et al. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27(1):29–34.
   PubMed Web of Science ®Google Scholar
• Yu GC, Wang LG, Han YY, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287.
   PubMed Web of Science ®Google Scholar
• Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):d808–15.
   PubMed Web of Science ®Google Scholar
• Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.
   PubMedGoogle Scholar
• Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–432.
   PubMed Web of Science ®Google Scholar
• Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinf. 2003;4:2.
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and Sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–407.
   PubMed Web of Science ®Google Scholar
• Silva R-E, Pinto AP, Pirmez R, et al. Dermatomyositis–part 1: definition, epidemiology, etiology and pathogenesis, and clinics. Skinmed. 2016;14(4):273–279.
   PubMedGoogle Scholar
• Luo S, Wang Y, Zhao M, et al. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. Int Immunopharmacol. 2016;40:542–549.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhao M, Chang C, et al. Type I interferons in the pathogenesis and treatment of autoimmune diseases. Clin Rev Allergy Immunol. 2020;59(2):248–272.
   PubMed Web of Science ®Google Scholar
• Gallay L, Mouchiroud G, Chazaud B. Interferon-signature in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2019;31(6):634–642.
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019;93(12):e1193–e204.
   PubMed Web of Science ®Google Scholar
• Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784–3792.
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664–678.
   PubMed Web of Science ®Google Scholar
• Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1–2):59–68.
   PubMed Web of Science ®Google Scholar
• Wong D, Kea B, Pesich R, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012;7(1):e29161.
   PubMed Web of Science ®Google Scholar
• Shen M, Duan C, Xie C, et al. Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. Front Immunol. 2022;13:962393.
   PubMed Web of Science ®Google Scholar
• Fang Q, Li T, Chen P, et al. Comparative analysis on abnormal methylome of differentially expressed genes and disease pathways in the immune cells of RA and SLE. Front Immunol. 2021;12:668007.
   PubMed Web of Science ®Google Scholar
• Fan H, Zhao G, Ren D, et al. Gender differences of B cell signature related to estrogen-induced IFI44L/BAFF in systemic lupus erythematosus. Immunol Lett. 2017;181:71–78.
   PubMed Web of Science ®Google Scholar
• Zheng JN, Li Y, Yan YM, et al. Identification and validation of key genes associated with systemic Sclerosis-Related pulmonary hypertension. Front Genet. 2020;11:816.
   PubMed Web of Science ®Google Scholar
• Piera-Velazquez S, Mendoza FA, Addya S, et al. Increased expression of interferon regulated and antiviral response genes in CD31+/CD102+ lung microvascular endothelial cells from systemic sclerosis patients with end-stage interstitial lung disease. Clin Exp Rheumatol. 2021;39(6):1298–1306.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zheng J, Zhou Y, et al. Knockdown of RSAD2 attenuates B cell hyperactivity in patients with primary sjogren’s syndrome (pSS) via suppressing NF-kappab signaling pathway. Mol Cell Biochem. 2021;476(5):2029–2037.
   PubMed Web of Science ®Google Scholar
• Maria NI, Steenwijk EC, IJpma AS, et al. Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2017;76(4):721–730.
   PubMed Web of Science ®Google Scholar
• Tang J, Tang A, Du H, et al. Peste des petits ruminants virus exhibits Cell-Dependent interferon active response. Front Cell Infect Microbiol. 2022;12:874936.
   PubMed Web of Science ®Google Scholar
• Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20(7):397–398.
   PubMed Web of Science ®Google Scholar
• Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol. 2020;146(1):206–208 e2.
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng YG, Tam C, et al. Transcriptional profiling and machine learning unveil a concordant biosignature of type I Interferon-Inducible host response across nasal swab and pulmonary tissue for COVID-19 diagnosis. Front Immunol. 2021;12:733171.
   PubMed Web of Science ®Google Scholar
• Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 2020;5(49):eabd1554.
   Web of Science ®Google Scholar